NASDAQ:DYN

Dyne Therapeutics (DYN) Stock Forecast, Price & News

$12.66

+0.19 (+1.52%)

(As of 05/26/2023 04:00 PM ET)

Compare

Today's Range: $12.43
▼
$12.91
50-Day Range: $8.53
▼
$14.28
52-Week Range: $4.30
▼
$15.63

Volume: 207,700 shs
Average Volume: 353,408 shs
Market Capitalization: $738.20 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $25.83

Dyne Therapeutics MarketRank™ Forecast

Analyst Rating: Buy
3.25 Rating Score
Upside/Downside: 104.1% Upside
$25.83 Price Target
Short Interest: Bearish
15.99% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.61
Based on 7 Articles This Week
Insider Trading: Selling Shares
$38,257 Sold Last Quarter
Proj. Earnings Growth: Decreasing
From ($3.18) to ($3.31) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.89 out of 5 stars

Medical Sector

732nd out of 1,010 stocks

Pharmaceutical Preparations Industry

370th out of 494 stocks

3.6

Analyst's Opinion

Consensus Rating
Dyne Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.25, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $25.83, Dyne Therapeutics has a forecasted upside of 104.1% from its current price of $12.66.
Amount of Analyst Coverage
Dyne Therapeutics has only been the subject of 1 research reports in the past 90 days.

0.0

Short Interest

Percentage of Shares Shorted
15.99% of the float of Dyne Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Dyne Therapeutics has a short interest ratio ("days to cover") of 12.6, which indicates bearish sentiment.
Change versus previous month
Short interest in Dyne Therapeutics has recently increased by 2.25%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Dyne Therapeutics does not currently pay a dividend.
Dividend Growth
Dyne Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for DYN.

2.0

News and Social Media Coverage

News Sentiment
Dyne Therapeutics has a news sentiment score of 0.61. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.76 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 7 news articles for Dyne Therapeutics this week, compared to 2 articles on an average week.

4.2

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Dyne Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $38,257.00 in company stock.
Percentage Held by Insiders
32.89% of the stock of Dyne Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
85.50% of the stock of Dyne Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Dyne Therapeutics are expected to decrease in the coming year, from ($3.18) to ($3.31) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Dyne Therapeutics is -3.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Dyne Therapeutics is -3.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Dyne Therapeutics has a P/B Ratio of 2.62. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Dyne Therapeutics (NASDAQ:DYN) Stock

Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. The company was incorporated in 2017 and is headquartered in Waltham, Massachusetts..

Receive DYN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Dyne Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

DYN Stock News Headlines

May 28, 2023 | msn.com

Dyne Therapeutics: FORCE Platform Poised To Revolutionize Gene Therapy

May 26, 2023 | americanbankingnews.com

Dyne Therapeutics (NASDAQ:DYN) Shares Down 5.8%

May 29, 2023 | Legacy Research (Affiliate) (Ad)

Sell every Stock except ONE

Markets are down...But Jeff Clark couldn't care less because he ignores almost every stock in the market except ONE. He lives financially free trading this One Stock Once per month...

May 25, 2023 | msn.com

Dyne's muscle disorder therapy DYNE-101 gets orphan drug status in EU

May 25, 2023 | markets.businessinsider.com

Dyne Therapeutics' DYNE-101 Granted Orphan Drug Designation By EMA

May 25, 2023 | finance.yahoo.com

Dyne Therapeutics Receives European Medicines Agency (EMA) Orphan Drug Designation for DYNE-101

May 23, 2023 | americanbankingnews.com

StockNews.com Upgrades Dyne Therapeutics (NYSE:DYN) to Hold

May 17, 2023 | finance.yahoo.com

We're Keeping An Eye On Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Rate

May 29, 2023 | Altimetry (Ad)

Pentagon Consultant—Here's how Biden Wins Landslide Re-election

—but also hand Joe Biden a landslide re-election win. What would America look like if we slide further towards Socialism? Full story and 4 steps you can take,

May 17, 2023 | finance.yahoo.com

Dyne Therapeutics’ Preclinical Data Demonstrating FORCE™ Platform Delivery to CNS Featured in Oral Presentation at ASGCT Annual Meeting

May 16, 2023 | americanbankingnews.com

Dyne Therapeutics (NASDAQ:DYN) Rating Lowered to Sell at StockNews.com

May 14, 2023 | americanbankingnews.com

Dyne Therapeutics (NYSE:DYN) Lowered to "Sell" at StockNews.com

May 11, 2023 | finanznachrichten.de

Dyne Therapeutics, Inc.: Dyne Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights

May 11, 2023 | msn.com

Dyne Therapeutics: Q1 Earnings Insights

May 11, 2023 | finance.yahoo.com

Dyne Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights

May 11, 2023 | americanbankingnews.com

Analysts Set Dyne Therapeutics, Inc. (NASDAQ:DYN) Price Target at $25.83

May 5, 2023 | americanbankingnews.com

Dyne Therapeutics (NASDAQ:DYN) Sees Large Volume Increase

May 3, 2023 | finance.yahoo.com

Dyne Therapeutics to Present at BofA Securities 2023 Healthcare Conference

May 2, 2023 | finance.yahoo.com

Dyne Therapeutics to Present New Preclinical Data at ASGCT Annual Meeting Demonstrating FORCE™ Platform Delivery to CNS

April 16, 2023 | americanbankingnews.com

Dyne Therapeutics, Inc. (NASDAQ:DYN) Receives Consensus Rating of "Buy" from Brokerages

April 6, 2023 | americanbankingnews.com

Dyne Therapeutics (NYSE:DYN) Shares Down 6.3%

April 6, 2023 | americanbankingnews.com

Dyne Therapeutics (NASDAQ:DYN) Stock Price Down 6.6%

March 25, 2023 | americanbankingnews.com

Dyne Therapeutics (NASDAQ:DYN) Trading Down 3.1%

March 25, 2023 | americanbankingnews.com

Dyne Therapeutics (NYSE:DYN) Stock Price Down 3.1%

March 23, 2023 | markets.businessinsider.com

Dyne Therapeutics Announces Orphan Drug And Rare Pediatric Designations For DYNE-251

March 23, 2023 | marketwatch.com

Dyne Gets FDA Orphan, Rare-Pediatric-Disease Designations for DYNE-251 >DYN

March 23, 2023 | finance.yahoo.com

Dyne Therapeutics Receives FDA Orphan Drug and Rare Pediatric Designations for DYNE-251 for the Treatment of Duchenne Muscular Dystrophy

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive DYN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Dyne Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

DYN Company Calendar

Last Earnings: 3/02/2023
Today: 5/29/2023
Next Earnings (Estimated): 8/03/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:DYN
CUSIP: N/A
CIK: 1818794
Web: www.dyne-tx.com
Phone: 781-786-8230
Fax: 781-786-8866
Employees: 93
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $25.83
High Stock Price Forecast: $34.00
Low Stock Price Forecast: $18.00
Forecasted Upside/Downside: +104.1%
Consensus Rating: Buy
Rating Score (0-4): 3.25
Research Coverage: 4 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($3.33)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-168,100,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -68.55%
Return on Assets: -57.25%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 11.55
Quick Ratio: 11.54

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $4.15 per share
Price / Book: 3.05

Miscellaneous

Outstanding Shares: 58,310,000
Free Float: 39,133,000
Market Cap: $738.20 million
Optionable: Not Optionable
Beta: 0.23

Key Executives

Mr. Joshua T. Brumm (Age 44)
CEO, Pres & Director
Comp: $1.03M

Ms. Susanna Gatti High M.B.A. (Age 54)
Chief Operating Officer
Comp: $646.93k

Dr. Oxana Beskrovnaya Ph.D. (Age 61)
Chief Scientific Officer
Comp: $609.44k

Dr. Romesh Subramanian Ph.D. (Age 57)
Co-Founder & Advisor

Mr. Gene Kim (Age 45)
VP of Fin.

Mr. Richard William Scalzo M.B.A. (Age 36)
Sr. VP, Head of Fin. & Admin. and Treasurer

Ms. Amy Reilly (Age 48)
Sr. VP and Head of Corp. Communications & Investor Relations

Ms. Kate Mitchell
VP & Head of HR

Dr. Thomas-Christian Mix M.D. (Age 55)
M.S., Sr. VP of Pharmacovigilance

Ms. Debra Feldman (Age 52)
Sr. VP & Head of Regulatory Affairs

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

DYN Stock - Frequently Asked Questions

Should I buy or sell Dyne Therapeutics stock right now?: 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Dyne Therapeutics in the last year. There are currently 3 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" DYN shares.
View DYN analyst ratings or view top-rated stocks.
What is Dyne Therapeutics' stock price forecast for 2023?: 4 Wall Street research analysts have issued twelve-month price targets for Dyne Therapeutics' stock. Their DYN share price forecasts range from $18.00 to $34.00. On average, they anticipate the company's share price to reach $25.83 in the next twelve months. This suggests a possible upside of 104.1% from the stock's current price.
View analysts price targets for DYN or view top-rated stocks among Wall Street analysts.
How have DYN shares performed in 2023?: Dyne Therapeutics' stock was trading at $11.59 at the start of the year. Since then, DYN shares have increased by 9.2% and is now trading at $12.66.
View the best growth stocks for 2023 here.
When is Dyne Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023.
View our DYN earnings forecast.
How were Dyne Therapeutics' earnings last quarter?: Dyne Therapeutics, Inc. (NASDAQ:DYN) announced its quarterly earnings results on Thursday, March, 2nd. The company reported ($0.74) earnings per share for the quarter, beating analysts' consensus estimates of ($0.84) by $0.10.
What ETFs hold Dyne Therapeutics' stock?: ETFs with the largest weight of Dyne Therapeutics (NASDAQ:DYN) stock in their portfolio include Direxion mRNA ETF (MSGR), Inspire Fidelis Multi Factor ETF (FDLS), Virtus LifeSci Biotech Clinical Trials ETF (BBC), iShares Neuroscience and Healthcare ETF (IBRN), Invesco Raymond James SB-1 Equity ETF (RYJ), AdvisorShares Dorsey Wright Micro-Cap ETF (DWMC), Invesco DWA SmallCap Momentum ETF (DWAS) and Principal Healthcare Innovators ETF (BTEC).

When did Dyne Therapeutics IPO?: (DYN) raised $175 million in an initial public offering (IPO) on Thursday, September 17th 2020. The company issued 10,300,000 shares at a price of $16.00-$18.00 per share. JPMorgan, Jefferies, Piper Sandler and Stifel served as the underwriters for the IPO.
What is Dyne Therapeutics' stock symbol?: Dyne Therapeutics trades on the NASDAQ under the ticker symbol "DYN."
Who are Dyne Therapeutics' major shareholders?: Dyne Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Atlas Venture Life Science Advisors LLC (16.95%), Wasatch Advisors LP (5.02%), Franklin Resources Inc. (3.25%), Logos Global Management LP (2.92%), Braidwell LP (2.36%) and Dimensional Fund Advisors LP (1.13%). Insiders that own company stock include Jason P Rhodes, Jonathan Mcneill, Joshua T Brumm, Richard William Scalzo, Susanna Gatti High and Wildon Farwell.
View institutional ownership trends.
How do I buy shares of Dyne Therapeutics?: Shares of DYN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Dyne Therapeutics' stock price today?: One share of DYN stock can currently be purchased for approximately $12.66.
How much money does Dyne Therapeutics make?: Dyne Therapeutics (NASDAQ:DYN) has a market capitalization of $738.20 million. The company earns $-168,100,000.00 in net income (profit) each year or ($3.33) on an earnings per share basis.
How can I contact Dyne Therapeutics?: The official website for the company is www.dyne-tx.com. The company can be reached via phone at 781-786-8230, via email at ir@dyne-tx.com, or via fax at 781-786-8866.

This page (NASDAQ:DYN) was last updated on 5/29/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial